<DOC>
	<DOCNO>NCT01212887</DOCNO>
	<brief_summary>RATIONALE : Placing gene T cell may improve body 's ability recognize cancer cell build immune response fight cancer . Drugs use chemotherapy , cyclophosphamide fludarabine phosphate , work different way stop growth tumor cell , either kill cell stop dividing . Biological therapy , aldesleukin , may stimulate immune system different way stop cancer cell grow . Giving specially treat T cell together cyclophosphamide , fludarabine phosphate , aldesleukin may kill tumor cell . PURPOSE : This phase I clinical trial study side effect best dose treat T cell give together cyclophosphamide , fludarabine phosphate , aldesleukin treat patient cancer .</brief_summary>
	<brief_title>Treated Blood Cells , Cyclophosphamide , Fludarabine Phosphate , Aldesleukin Treating Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate feasibility MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes combination precondition chemotherapy comprise cyclophosphamide fludarabine phosphate plus aldesleukin patient CEA-positive tumor . - To assess toxicity regimen patient . - To determine dose MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes require give optimal survival cell circulation ( recommended phase II dose ) . Secondary - To assess whether MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes isolated circulation functional . - To determine preliminary tumor response MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes . - To evaluate safety MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes . OUTLINE : This phase I , dose-escalation study MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes . Patients undergo leukapheresis 7-14 day study therapy begin . Cells transduce retrovirus vector expand produce MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes . Patients receive precondition chemotherapy comprise fludarabine phosphate IV 15 minute day -5 -1 cyclophosphamide IV 1 hour day -7 -6 fludarabine phosphate IV 15 minute day -5 -1 . They receive MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes IV 30 minute day 0 . Patients also receive high-dose aldesleukin IV 15 minute every 8 hour 12 dos begin day 0 , absence disease progression unacceptable toxicity . If evidence MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes survival , patient may receive additional high-dose aldesleukin . Patients undergo blood sample collection periodically pharmacokinetic pharmacodynamic study . Some patient may undergo tumor biopsy . After completion study treatment , patient follow every 2 week 6 week , every 4 week 6 month , every 3 month 1 year , every 6 month thereafter . Peer Reviewed Funded Endorsed Cancer Research UK</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy Metastatic unresectable disease Standard curative palliative measure exist , longer effective , complete , refuse CEApositive tumor ( either immunohistochemistry demonstrate elevated CEA &gt; 50 μg/L ) No primary brain tumor brain metastasis PATIENT CHARACTERISTICS : WHO performance status 01 Life expectancy ≥ 3 month Hemoglobin ≥ 10 g/dL Platelet count ≥ 100 x 10^9/L Neutrophil count ≥ 2.0 x 10^9/L Lymphocyte count ≥ 1.0 x 10^9/L Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT/AST ≤ 5 time ULN Alkaline phosphatase ≤ 5 time ULN Calculated creatinine clearance OR isotope clearance measurement ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week prior , , 6 month completion study therapy ( male patient must use barriermethod contraception ) LVEF ≥ 50 % MUGA scan ( patient receive cyclophosphamide ) ECG exercise ECG ( stress ECHO ) normal ( may abnormal clinically significant ) Urine dipstick normal ( may abnormal clinically significant ) No medical high risk due nonmalignant systemic disease include active uncontrolled infection No known serologically positive hepatitis B , hepatitis C , HIV , HTLV No history autoimmune disease No inflammatory bowel disease No concurrent congestive heart failure prior history NYHA class IIIIV cardiac disease No concurrent malignancy originate primary site , except adequately treat conebiopsied carcinoma situ cervix uteri basal cell squamous cell carcinoma skin No condition , investigator 's opinion , would make patient unsuitable candidate clinical trial PRIOR CONCURRENT THERAPY : At least 30 day since prior concurrent participation another clinical trial At least 4 week since prior concurrent radiotherapy ( except palliative reason [ i.e. , control bone pain ] ) At least 4 week since prior concurrent endocrine therapy , immunotherapy , chemotherapy ( 6 week nitrosoureas mitomycin C ) No toxic manifestation previous treatment , except alopecia certain grade 1 toxicity , opinion investigator CRUK ( Cancer Research UK ) , would exclude patient ( e.g. , grade 1 neuropathy grade 1 fatigue ) No prior major thoracic and/or abdominal surgery patient yet recover No prior bone marrow transplant extensive radiotherapy &gt; 25 % bone marrow No concurrent systemic steroid immunosuppressive therapy No concurrent anticancer therapy investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IIIA colon cancer</keyword>
	<keyword>stage IIIB colon cancer</keyword>
	<keyword>stage IIIC colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IVB colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IIIA rectal cancer</keyword>
	<keyword>stage IIIB rectal cancer</keyword>
	<keyword>stage IIIC rectal cancer</keyword>
	<keyword>stage IVA rectal cancer</keyword>
	<keyword>stage IVB rectal cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIA ovarian germ cell tumor</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian germ cell tumor</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
</DOC>